Back to Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 2
Memantine combined with an acetyl cholinesterase inhibitor – hope for the future?
Authors Chris Fox, Ian D Maidment, Malaz Boustani, Cornelius Katona
Published 15 June 2006 Volume 2006:2(2) Pages 121—125
Chris Fox1, Ian D Maidment2, Malaz Boustani3, Cornelius Katona4
1,2East Kent NHS and Social Care Partnership Trust, Kent Institute of Medicine and Health Sciences, University of Kent at Canterbury, UK; 3Regenstrief Institute and Indiana University Center for Aging Research, Indianapolis, IN, USA; 4Kent Institute of Medicine and Health Sciences, University of Kent at Canterbury, UK
Background: Memantine and cholinesterase inhibitors (ChEI) have distinct pharmacological actions, and interest in the use of combination therapy for Alzheimer’s disease (AD) is increasing.
Objective: To assess the available data on the use of memantine–ChEI combination and to develop evidence-based recommendations.Method: A systematic literature review with detailed discussion of the current evidence base.
Results: Available data are limited: five studies of which two were randomized, double-blind, placebo-controlled trials. One study indicated that memantine–ChEI combination is not significantly more effective than placebo–ChEI in mild to moderate AD, but data were published in abstract and poster form only. A second study indicated that the memantine–ChEI combination is significantly more effective than placebo–ChEI in moderate to severe AD. The calculated effect sizes of 0.36 on cognition and 0.12 on function, which were the primary outcomes, were small, indicating a clinically minimal effect on cognition and no effect on function. No data are available on whether combination treatment is more effective than memantine monotherapy.
Conclusion: The available data do not justify the use of combination therapy. Future studies should include three arms (memantine–placebo, placebo–ChEI, and memantine–ChEI), be of an adequate size and duration, and use pragmatic measures. Clinicians should have full access to data from any future trials.
Keywords: memantine, cholinesterase inhibitors, combination, Alzheimer’s disease, randomised control studies, open-label studies